Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 13/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 4/20 | 0.37 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.37 |
| ▸ | FEN1 | P39748 | 2/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL269249 | 0.91 | SCN9A (0.48) | SCN9ACTSSCTSKSCN10AANO1 | |
| SCHEMBL277718 | 0.90 | SCN9A (0.41) | SCN9ACTSSCTSKSCN10AANO1 | |
| SCHEMBL268932 | 0.90 | ANO1 (0.43) | SCN9ACTSSCTSKSCN10AANO1 | |
| SCHEMBL268422 | 0.88 | CTSS (0.51) | SCN9ACTSSCTSKSCN10AANO1 | |
| SCHEMBL277955 | 0.86 | CTSS (0.40) | SCN9ACTSSCTSKSCN10AANO1 | |
| SCHEMBL277567 | 0.85 | SCN9A (0.43) | SCN9ACTSSCTSKSCN10AANO1 | |
| SCHEMBL268189 | 0.85 | ALOX5AP (0.37) | SCN9ACTSSCTSKSCN10AANO1 | |
| SCHEMBL269012 | 0.85 | PTPN1 (0.42) | SCN9ACTSSCTSKPTPN1CYP3A4 | |
| SCHEMBL270332 | 0.83 | SCN9A (0.49) | SCN9ACTSSCTSKSCN10AANO1 | |
| SCHEMBL268438 | 0.83 | SCN9A (0.40) | SCN9ASCN10AANO1CYP3A4ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133907-B2 | Type II diabetes, obesity, hyperglycemia and a lipid disorder selected from dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL and high LDL; additionally comprising metformin | ELI LILLY AND COMPANY (US) | 2012-03-13 | — | — | US | disclosed |
| EP-1912946-B1 | PYRIDINE DERIVATIVES AS DIPEPTEDYL PEPTIDASE INHIBITORS | LILLY CO ELI (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080214616-A1 | Pyridine Derivatives as Dipeptedyl Peptidase Inhibitors | ELI LILLY AND COMPANY | 2008-09-04 | — | — | US | disclosed |
| EP-1912946-A1 | PYRIDINE DERIVATIVES AS DIPEPTEDYL PEPTIDASE INHIBITORS | Eli Lilly and Company (US) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007015767-A1 | PYRIDINE DERIVATIVES AS DIPEPTEDYL PEPTIDASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214616-A1 | Pyridine Derivatives as Dipeptedyl Peptidase Inhibitors | DPP4, DPP3, DPP7 | SCN9A 1412/4885CTSS 1680/4885CTSK 2589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.